Pfizer's Abrysvo Hits Key Goals in Adults at Increased RSV Risk
By Colin Kellaher
Pfizer's Abrysvo vaccine for respiratory syncytial virus, or RSV, has met the key goals of a late-stage study in adults who are at increased risk of developing severe illness related to the virus.
Pfizer on Tuesday said the Phase 3 study evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age who are at risk of developing severe RSV-associated lower respiratory tract disease met its co-primary immunogenicity endpoints as well as its primary safety endpoint.
Pfizer said adults with certain underlying chronic conditions, such as asthma, diabetes and chronic obstructive pulmonary disease. are at increased risk of developing and being hospitalized for RSV-associated illness.
The U.S. Food and Drug Administration last year approved Abrysvo for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older and to help protect infants at birth through six months of life from lower respiratory tract disease due to RSV by active immunization of pregnant women.
New York drugmaker Pfizer on Tuesday said it plans to submit the new study data to regulatory agencies and to request expansion of the Abrysvo age group from the current indication to include adults 18 years of age and older.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 09, 2024 06:59 ET (10:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom